Comparison of the baseline independent predictive factors for fibrosis in the four cohorts of patients with chronic hepatitis C.

<p>Only factors found by univariate analysis to be significant in at least one of the four groups are reported.</p>*<p>Male as reference; § Not included in multivariate model because not significant in univariate analysis.</p><p>HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; OR, odds ratio; CI, confidence interval.</p

Univariate and multivariate analysis for fibrosis in the whole cohort of patients with chronic hepatitis C.

<p>Only factors found to be significant by univariate analysis are reported.</p>*<p>Male as reference. HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; OR, odds ratio; CI, confidence interval.</p

Estradiol and Testosterone serum levels and E2/T ratio in men and women divided according to women’s reproductive phases as described in Methods.

<p>Values (reported as mean±SD) were compared by Mann-Whitney test. The levels of significance are reported in the text.</p

Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.

<p>Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.</p

Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.

<p>Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.</p

The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.

<p>The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.</p

Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.

<p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p

Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients.

<p>Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.</p

Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).

<p>Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).</p

Univariate and logistic regression analysis linking failure with independent variables.

<p>Univariate and logistic regression analysis linking failure with independent variables.</p